Abstract: A system and method with improved water management for the electrochemical conversion of a gaseous compound, in particular CO2, in a zero-gap electrolyzer comprises the direct injection of a liquid, such as water, in the gaseous feed comprising the gaseous compound (CO2) and providing the gas/liquid mixture to the membrane electrode assembly of the zero-gap electrolyser via an interdigitated flow channel. This way, the gas and the liquid are forced through the porous electrode structures, thus ensuring that both the liquid and the gaseous compound (CO2) are in close contact with the electrode, resulting in an improved hydration of the electrode and an efficient conversion of the gaseous compound (CO2).

Abstract: Mucins and isoforms thereof are provided herein for use in the diagnosis, monitoring, prevention, and/or treatment of a disease characterized by barrier dysfunction, such as, but not limited to a gastrointestinal disorder (e.g. Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), cancer, gastrointestinal infections, obesitas, non-alcoholic fatty liver disease (NAFLD)), neurodegenerative disorders, respiratory infections, and more in particular coronaviral infections. In a specific embodiment, said mucins and/or isoforms thereof are selected from the list comprising: MUC16, MUC21, MUC20, MUC2, MUC4, MUC5AC, MUC5B, MUC13, and MUC1, and isoforms thereof.

Abstract: The present invention relates to the field of mucin isoforms, more in particular for use in the diagnosis, monitoring, prevention and/or treatment of a disease characterized by barrier dysfunction, such as but not limited to a gastrointestinal disorder (e.g. Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), cancer, gastro-intestinal infections, obesitas, non-alcoholic fatty liver disease (NAFLD)), neurodegenerative disorders, respiratory infections, . . . In a specific embodiment, said mucin isoform is selected from the list comprising: MUC1 isoforms and MUC13 isoforms.